Skip to content

The efficacy and safety of premarin, estrogel, estrana tape for thawed blastocyst transfer in patients with infertility - A prospective randomized controlled trial

The efficacy and safety of premarin, estrogel, estrana tape for thawed blastocyst transfer in patients with infertility - A prospective randomized controlled trial - The efficacy and safety of premarin, estrogel, estrana tape for thawed blastocyst transfer in patients with infertility - A prospective randomized controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000016919
Enrollment
300
Registered
2015-03-26
Start date
2015-01-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

Oral administration of premarin (0.632mg per tablet, twice a day). Continuous administration until pregnancy determination date from the second day of menstruation. Estrogel (2.16mg per day in Estr

Sponsors

Oak Clinic Group
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Infertile patients. Provided written informed consent.

Exclusion criteria

Exclusion criteria: Patients that fall into contraindication to estrogel, premarin and estrana tape.

Design outcomes

Primary

MeasureTime frame
Clinical pregnancy rate, Birth rate

Secondary

MeasureTime frame
Ongoing pregnancy rate

Countries

Japan

Contacts

Public ContactSagiri Taguchi

Oak Clinic Group IVF Center

taguchi_s@oakclinic-group.com06-4398-1000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026